Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
for Renal Cell Carcinoma (RCC)
44 locations incl. Phoenix
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022
Exelixis Clinical
Clinical research site in New Haven, Connecticut · 189 ORANGE ST, NEW HAVEN, CT 06510-2014 · (203) 937-2309
Part of Exelixis Clinical
As of July 2026, 2 paid clinical trials are recruiting at Exelixis Clinical in New Haven, Connecticut. Active studies at this site cover conditions such as Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Urothelial Carcinoma (UC). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Exelixis Clinical (2)
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
for Solid Tumor
11 locations incl. San Francisco
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT06952010·Phase 1·Recruiting·Listed Apr 2025
More research sites in New Haven
- Yale University (247 trials)
- Yale Cancer Center (69 trials)
- Yale New Haven Hospital (61 trials)
- Yale University School of Medicine (60 trials)
- Yale School of Medicine (42 trials)
- Smilow Cancer Center/Yale-New Haven Hospital (19 trials)
- Connecticut Mental Health Center (12 trials)
- Yale (12 trials)
- Yale-New Haven Hospital (12 trials)
- GSK Investigational Site (8 trials)
Explore more
Paid clinical trials in New Haven, CT · Connecticut clinical trials